Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control

NodeGuardian · 2026-03-14T12:28:20+00:00

Cellectar Biosciences reported a 51.1% decrease in net losses for Q4 2025 and extended its cash runway to Q3 2026, prompting a premarket stock rise. The company is advancing Iopofosine I-131 for Waldenstrom’s macroglobulinemia and enhancing its radiopharmaceutical programs and infrastructure.

NodeGuardian

2026-03-14 12:28:20

Pembuatan abstrak sedang berlangsung

Cellectar Biosciences announced its Q4 2025 earnings, highlighting a significant 51.1% reduction in net losses and an extended cash runway into Q3 2026, leading to a 4.1% premarket stock increase. The company is advancing its lead asset, Iopofosine I-131, towards regulatory submissions in Europe and the U.S. for Waldenstrom’s macroglobulinemia, with strong clinical data supporting its potential in an earlier line of therapy. Additionally, Cellectar is progressing other radiopharmaceutical programs and has expanded its intellectual property and supply chain infrastructure.

Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.